Immunomodulation and immunopharmacology in heart failure
- 14 September 2023
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 21 (2) , 119-149
Abstract
The immune system is intimately involved in the pathophysiology of heart failure. However, it is currently underused as a therapeutic target in the clinical setting. Moreover, the development of novel immunomodulatory therapies and their investigation for the treatment of patients with heart failure are hampered by the fact that currently used, evidence-based treatments for heart failure exert multiple immunomodulatory effects. In this Review, we discuss current knowledge on how evidence-based treatments for heart failure affect the immune system in addition to their primary mechanism of action, both to inform practising physicians about these pleiotropic actions and to create a framework for the development and application of future immunomodulatory therapies. We also delineate which subpopulations of patients with heart failure might benefit from immunomodulatory treatments. Furthermore, we summarize completed and ongoing clinical trials that assess immunomodulatory treatments in heart failure and present several therapeutic targets that could be investigated in the future. Lastly, we provide future directions to leverage the immunomodulatory potential of existing treatments and to foster the investigation of novel immunomodulatory therapeutics.Keywords
This publication has 385 references indexed in Scilit:
- Critical role for calcium mobilization in activation of the NLRP3 inflammasomeProceedings of the National Academy of Sciences, 2012
- Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytesJournal Of Hypertension, 2012
- Effect of Uremia on Structure and Function of Immune SystemJournal of Renal Nutrition, 2012
- Angiotensin-Converting Enzyme Inhibition Prevents the Release of Monocytes From Their Splenic Reservoir in Mice With Myocardial InfarctionCirculation Research, 2010
- Interleukin-6 stimulates epithelial sodium channels in mouse cortical collecting duct cellsAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2010
- Angiotensin-converting Enzyme Inhibition Down-regulates the Pro-atherogenic Chemokine Receptor 9 (CCR9)-Chemokine Ligand 25 (CCL25) AxisJournal of Biological Chemistry, 2010
- Regulation of T-cell function by endogenously produced angiotensin IIAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2009
- Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivoAtherosclerosis, 2009
- Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Toll-Like Receptor-4 Deficiency Attenuates Doxorubicin-Induced Cardiomyopathy in MiceEuropean Journal of Heart Failure, 2008